Appian Labs, a biopharmaceutical company specializing in advanced therapeutic design, has launched itself as a company focused on providing comprehensive and strategic drug delivery and design solutions for pharmaceutical and other bioactives companies worldwide. The company provides solutions for a number of drug delivery problems, including poor bioavailability or solubility, dose timing, toxicity and many others. Appian Labs is funded and managed by venture firm Emergent Technologies, Inc.
Appian's laboratory is led by chief scientist Nicholas Peppas, Sc.D., Dr. Peppas has published more than 1,050 peer-reviewed articles and 33 books, covering drug delivery, hydrogels, and related controlled release.
Brian Windsor, Ph.D., president of Appian Labs, said, "Building on the drug delivery leadership of our scientific team, we can design delivery solutions tailored to pharma companies' drugs and that improve bioavailability, dosing, or timing of a drug. Our breadth of expertise and technologies enables us to match virtually any kinetic profile desired.” The company's first marketing initiative to potential pharmaceutical partners is an invitation to 'Draw your own profile'; Appian Labs will design a custom drug delivery system to match.
Dr. Windsor added, "Having worked with pharmaceutical companies for several decades to solve drug delivery problems, our scientific team knows both the common needs and the far-reaching goals of drug manufacturers."
The company is named after the Appian Way, "the leading delivery route of the ancient world," according to a company statement.